By targeting metabolic pathways involving ACOXL, it may be possible to reverse the immune evasion and apoptosis resistance seen in gastric cancer, providing new avenues for treatment that directly address the metabolic reprogramming associated with cancer progression. This evidence concerns the gene ACOXL and gastric cancer.